Search for a trial

Characterizing the Tumor Immune Microenvironment of Head and Neck Squamous Cell Carcinoma

Characterize the tumor immune microenvironment (TiME) in head and neck squamous cell carcinoma (HNSCC). Specifically we want to understand which molecular and/or immunological mechanisms are different between different genetic subgroups of HNSCC (i.…

Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High-Intensity Focused Ultrasound Histotripsy; the iFOCUS study.

Primary objective: to determine 1) the safety, tolerability and feasibility of a single-session of HIFU-HT treatment with ICI (IV anti-PD-1; nivolumab + anti-CTLA-4; ipilimumab).Secondary objective: to evaluate clinical, radiological and…

Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally advanced stage non-small cell lung carcinoma

To assess the safety of cisplatin doublets with hypofractionated radiotherapy (24 x2.75Gy).

Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1

This study has been transitioned to CTIS with ID 2024-514907-32-00 check the CTIS register for the current data. To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality…

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients.

This study has been transitioned to CTIS with ID 2024-514919-10-00 check the CTIS register for the current data. To investigate if the use of weekly low dose cisplatin increases compliance to the planned chemotherapy scheme in LA-HNSCC patients with…

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

This study has been transitioned to CTIS with ID 2024-517150-10-00 check the CTIS register for the current data. Primary:- To evaluate the safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of…

A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY

Study MX39795 will compare the efficacy and safety of molecularly-guided therapy versusstandard platinum-containing chemotherapy in patients with poor prognosis cancer of unknown primary site(CUP; non-specific subset) who have achieved disease…

A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies;Study ITCC 053

This study has been transitioned to CTIS with ID 2023-504880-18-00 check the CTIS register for the current data. Primary• To determine the RP2D of crizotinib in combination with temsirolimus • To determine the safety and preliminary activity of…

A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)

This study has been transitioned to CTIS with ID 2023-507170-41-00 check the CTIS register for the current data. Primary:Phase I: • To identify the maximum tolerated dose (MTD) and/or Recommended Phase II dose (RP2D) of [177Lu]-NeoB Phase IIa:•…

A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)

Primary Objectives:• To characterize the safety and tolerability and to identify the recommended Phase 2 dose (RP2D) of ALKS 4230 administered subcutaneously (SC) as lead-in monotherapy and in combination with pembrolizumab in subjects with advanced…

The effectiveness of patient-tailored interdisciplinary Medical Specialist Cancer Rehabilitation compared with allied health care on quality of life in patients with complex adverse effects of cancer or the treatment.

The research objectives of this study are divided in a primary research objective and secondary research objectives.Primary:1. To study the effectiveness on the short and long term of patient-tailored interdisciplinary MSCR compared with AHC on the…

The Drug Rediscovery Protocol (DRUP trial)
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

This study has been transitioned to CTIS with ID 2023-509152-33-00 check the CTIS register for the current data. Primary Objectives• To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for…

An open-label, multi-center, phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors

This study has been transitioned to CTIS with ID 2023-508925-29-00 check the CTIS register for the current data. Primary: To characterize safety and tolerability of TNO155 and identify a recommended dose and regimen for future studies in adult…

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination
with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors

To assess the effect of MEDI4736 in combination with olaparib±bevacizumab in patients with selected advanced solid tumors.To assess the safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) in patients with selected…

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination with cemiplimab in Adult Patients with Advanced Solid Tumors

Primary Objectives:Dose escalation (Part 1)Part 1A (SAR439459 monotherapy)-To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with…

ADJUSTment Disorder in Cancer Patients: Effectiveness and Cost-Utility of Tailored Psychological Treatment

The ultimate aim of this project is to provide scientific evidence on tailored psychological interventions for cancer patients with an adjustment disorder. This study investigated the effectiveness, cost-utility and budget impact of a tailored…

Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy

This study has been transitioned to CTIS with ID 2023-503554-12-00 check the CTIS register for the current data. The primary objective of the study is to describe the pharmacokinetics of Nivolumab (how quickly it is absorbed by the body) when…

A Phase I, open-label, dose escalation study of oral LGK974 in patients malignancies dependent on Wnt ligands

Primair:Determine the MTD and/or recommended dose for expansion (RDE) of LGK974 as a single agent andin combination with PDR001 when administered to adult patients with malignancies dependent on Wntligands as specified in the inclusion…

Nutritional prehabilitation in head and neck cancer patients with sarcopenia: a randomized controlled trial

To investigate the effect of nutritional prehabilitation on adverse events in patients with locoregionally advanced head and neck cancer, with low to medium risk of malnutrition and with radiological sarcopenia. To evaluate its effect on patient-…

Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin

This study has been transitioned to CTIS with ID 2023-507582-25-00 check the CTIS register for the current data. PRIMARY OBJECTIVESThe primary objective of MAKEI V is to assess in a randomized comparison whether the efficacy of Carboplatin (600 mg/…